Gilead Launches Donations Program to Break Barriers in Hepatitis B Treatments Gilead Sciences has initiated a donation program designed to eliminate barriers in screening and treatment for Hepatitis B, supporting non-profits.

Gilead Launches Donations Program to Break Barriers in Hepatitis B Treatments #Japan #Hepatitis_B #Gilead_Sciences #Chiyoda #medical_donations

Pictor's Revolutionary Test Set to Enhance Hepatitis B Immunity Assessment Amid CDC Guidelines With new CDC recommendations, Pictor's ViraScreen-Core™ assay transforms hepatitis B immunity testing, improving public health impact and lab efficiency.

Pictor's Revolutionary Test Set to Enhance Hepatitis B Immunity Assessment Amid CDC Guidelines #USA #Carlsbad #Hepatitis_B #Pictor_Holdings #ViraScreen-Core

AusperBio's AHB-137 Shows Promising Results for Hepatitis B Treatment AusperBio's recent findings on AHB-137's effectiveness in treating chronic hepatitis B offer new hope, achieving a 30% functional cure rate in patients.

AusperBio's AHB-137 Shows Promising Results for Hepatitis B Treatment #USA #San_Francisco #AusperBio #Hepatitis_B #AHA-137

Hep B Free Strives for Continued Hepatitis B Vaccination for Newborns Amid Federal Advisory Changes Hep B Free advocates for maintaining universal hepatitis B vaccination for newborns, emphasizing its vital role despite recent federal advisory changes in guidelines.

Hep B Free Strives for Continued Hepatitis B Vaccination for Newborns Amid Federal Advisory Changes #United_States #San_Francisco #Vaccination #Hepatitis_B #Hep_B_Free

Concerns Raised Over Delays in Hepatitis B Compensation Review Process The AdIre Law Office expresses serious concerns about the ongoing delays and prolonged review periods under the Hepatitis B compensation system.

Concerns Raised Over Delays in Hepatitis B Compensation Review Process #Japan #Tokyo #Hepatitis_B #Adire_Law #Compensation_Delay

Hepatitis B and C Therapeutics Market Expected to Reach $17.02 Billion by 2024, Driven by Advances in Treatment and Screening Policies The Hepatitis B and C therapeutics market is projected to hit $17.02 billion by 2024, fueled by innovations in treatment and national screening strategies that enhance global healthcare.

Hepatitis B and C Therapeutics Market Expected to Reach $17.02 Billion by 2024, Driven by Advances in Treatment and Screening Policies #USA #Austin #Hepatitis_B #Hepatitis_C #Antivirals

Brii Biosciences Showcases Promising Phase 2 ENSURE Study Data at AASLD 2025 Brii Biosciences reveals groundbreaking data from the Phase 2 ENSURE study, highlighting the potential of BRII-179 in curing chronic Hepatitis B at AASLD 2025.

Brii Biosciences Showcases Promising Phase 2 ENSURE Study Data at AASLD 2025 #USA #Washington_D.C. #Hepatitis_B #BRII-179 #Brii_Biosciences

AusperBio Showcases 48-Week Phase II Data of AHB-137 for Chronic Hepatitis B at AASLD 2025 At the AASLD 2025 Annual Meeting, AusperBio revealed promising 48-week Phase II data for AHB-137, enhancing treatment for chronic hepatitis B.

AusperBio Showcases 48-Week Phase II Data of AHB-137 for Chronic Hepatitis B at AASLD 2025 #Washington_D.C. #AusperBio #AHB-137 #Hepatitis_B

AusperBio Achieves Milestone in AHB-137 Phase II Trials for Chronic Hepatitis B AusperBio Therapeutics has completed the enrollment for two pivotal Phase II trials of AHB-137, a potential treatment for chronic hepatitis B. The trials could redefine treatment strategies in the field.

AusperBio Achieves Milestone in AHB-137 Phase II Trials for Chronic Hepatitis B #USA #San_Francisco #AusperBio #AHB-137 #Hepatitis_B

Lion TCR's Approval Journey: Pioneering TCR-T Therapy for Chronic Hepatitis B Lion TCR recently achieved significant FDA milestones for its innovative therapy targeting chronic hepatitis B. This piece explores the importance of these advancements in biotechnology.

Lion TCR's Approval Journey: Pioneering TCR-T Therapy for Chronic Hepatitis B #USA #Singapore #TCR-T_Therapy #Hepatitis_B #Lion_TCR

Dynavax Technologies Unveils Strong Q2 2025 Results with Record Revenues Dynavax Technologies has reported impressive financial results for Q2 2025, marked by record revenues from its HEPLISAV-B vaccine and promising clinical updates.

Dynavax Technologies Unveils Strong Q2 2025 Results with Record Revenues #United_States #Emeryville #Hepatitis_B #Dynavax #HEPLISAV-B

Hep B Free Initiative Expands to Unite Advocates Nationwide in the Fight Against Hepatitis B On World Hepatitis Day, SF Hep B Free rebrands as Hep B Free, expanding its reach to unite advocates across the U.S. for hepatitis B awareness.

Hep B Free Initiative Expands to Unite Advocates Nationwide in the Fight Against Hepatitis B #United_States #San_Francisco #liver_cancer #Hepatitis_B #Hep_B_Free

SCG Cell Therapy's SCG101V Receives Approval for Clinical Trial in China for Hepatitis B Treatment SCG Cell Therapy has achieved a significant milestone with its investigational drug SCG101V, approved for clinical trials in China, targeting chronic hepatitis B.

SCG Cell Therapy's SCG101V Receives Approval for Clinical Trial in China for Hepatitis B Treatment #Singapore #SCG101 #SCG_Cell_Therapy #Hepatitis_B

Chronic Hepatitis B Market Growth Driven by Advancements and Rising Awareness in the US The chronic hepatitis B market is poised for significant growth in the US due to advancements in treatment options and increased awareness about the disease.

Chronic Hepatitis B Market Growth Driven by Advancements and Rising Awareness in the US #United_States #Las_Vegas #Hepatitis_B #Gilead_Sciences #VEMLIDY

AusperBio Secures $50 Million Funding to Enhance Chronic Hepatitis B Treatments AusperBio Therapeutics has successfully completed a $50 million Series B+ financing round to further develop innovative treatments for chronic hepatitis B.

AusperBio Secures $50 Million Funding to Enhance Chronic Hepatitis B Treatments #USA #San_Francisco #AusperBio #AHB-137 #Hepatitis_B

Dynavax Survey Reveals Americans Lack Awareness on Hepatitis B Risks and Vaccine Benefits A recent survey by Dynavax reveals a concerning lack of awareness among Americans regarding the dangers of hepatitis B and the importance of vaccination. Public education is essential.

Dynavax Survey Reveals Americans Lack Awareness on Hepatitis B Risks and Vaccine Benefits #United_States #Vaccination #Emeryville #Hepatitis_B #Dynavax

Adire Law Office Launches Dedicated Page for Hepatitis B Compensation Claims Adire Law Office has launched a special page aimed at assisting individuals with various issues related to Hepatitis B compensation claims, offering tailored advice.

Adire Law Office Launches Dedicated Page for Hepatitis B Compensation Claims #Japan #Tokyo #Hepatitis_B #Adire_Law #compensation_claims

Groundbreaking Study Shows Safer as Well as Effective Treatment for Chronic Hepatitis B A new study reveals that besifovir may provide a safer alternative to tenofovir for patients with chronic hepatitis B, improving kidney and bone health.

Groundbreaking Study Shows Safer as Well as Effective Treatment for Chronic Hepatitis B #South_Korea #Seoul #Hepatitis_B #Besifovir #Tenofovir

AusperBio Achieves $73 Million in Series B Funding to Combat Chronic Hepatitis B AusperBio has successfully closed a $73 million Series B financing round to enhance its efforts in developing a functional cure for chronic hepatitis B, showcasing investor confidence.

AusperBio Achieves $73 Million in Series B Funding to Combat Chronic Hepatitis B #USA #San_Francisco #AusperBio #AHB-137 #Hepatitis_B

◾️ #Kirillov blamed the #Pentagon for blowing up the #Kakhovka hydroelectric power station dam. He claimed that the #Pentagon was trying to create populations of small insects capable of carrying dangerous diseases—#Ebola fever, #hepatitis_B, #AIDS, and severe acute respiratory syndrome.